Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Artisan Partners Small Cap Fund 2024 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (Artisan Partners Small Cap Fund)

Primary Source Intelligence • Q1 2024 Letter Analysis

Artisan Partners Small Cap Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Artisan Partners Small Cap Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+9.19%

Digest Analysis

Quick Take

"Artisan Small Cap underperformed in Q4 despite positive absolute returns, hurt by biotech R&D setbacks and semiconductor cyclical pressures. Small caps rallied on soft landing optimism and Fed dovishness."

Executive Summary

Artisan Small Cap Fund delivered positive absolute returns in Q4 2023 but underperformed the Russell 2000 Growth Index, primarily due to security selection challenges in healthcare and information technology. The portfolio's biotechnology holdings faced R&D setbacks despite solid commercial progress, with Argenx, Halozyme, and Ascendis accounting for nearly 80% of 2023 underperformance. Semiconductor holdings experienced cyclical pressures, particularly Lattice Semiconductor, though the team expects secular trends to drive medium-term growth. Small-cap stocks rallied strongly in Q4 as investor sentiment shifted toward economic soft landing expectations following dovish Fed messaging. The team maintains conviction in their selective approach to biotechnology investing, focusing on de-risked assets with proven drugs and diversified pipelines. Portfolio activity included new positions in IPG Photonics, MYR Group, and elf Beauty, while exiting BlackLine, Shoals Technologies, and Freshpet. Looking ahead, the team believes they enter 2024 with attractive opportunities across sectors, supported by reasonable valuations for growth equities and powerful secular trends in AI, energy transition, and digitalization.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

High conviction evidenced by maintaining positions through significant underperformance (biotech holdings), adding to positions during weakness, and detailed thesis defense. Portfolio is concentrated with named, sized holdings and clear rationale for each position. The team demonstrates willingness to hold through volatility based on long-term conviction.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism about markets entering 2024, noting attractive opportunities and reasonable valuations for growth equities. However, they acknowledge continued macro-driven volatility and uncertainty, particularly around the presidential election. The outlook is constructive but measured.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

Portfolio positioning shows selective risk-taking with new Garden positions initiated, but also defensive moves like trimming successful positions and exiting underperformers. The team maintains conviction in existing holdings despite setbacks, suggesting moderate risk appetite with disciplined position management.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Moderate deployment activity with three new Garden positions initiated and selective adds to existing holdings like Exact Sciences and Repligen. However, this was balanced by trimming successful positions and exiting three holdings, suggesting measured net deployment rather than aggressive capital deployment.

Forward Guidance

20%

CautiousExpansionary

Cautious (20%)

The manager indicates selective deployment with new Garden positions and adds to existing holdings based on conviction. They express willingness to be patient through cycles and maintain positions despite volatility, suggesting a measured deployment bias rather than aggressive capital deployment.

Language Signal

30%

BearishBullish

Bearish (30%)

Language is balanced with more opportunity-focused terms like 'attractive opportunities,' 'reasonable valuations,' and 'powerful secular trends' than risk language. However, significant discussion of setbacks, underperformance, and challenges prevents a more bullish score.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Manager acknowledges multiple risk factors including macro volatility, election uncertainty, biotech funding concerns, and cyclical semiconductor pressures. However, risks are discussed as manageable within their investment framework rather than existential threats, suggesting moderate risk perception.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Manager expresses confidence in finding attractive opportunities across sectors, noting 'attractive opportunities across the sector landscape' and reasonable valuations. New positions were initiated and the team found selective opportunities despite challenging conditions, indicating good opportunity density.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

Clear multi-year investment horizon with willingness to hold through cyclical downturns and maintain positions despite near-term setbacks. The team discusses secular trends over 'medium and long-term horizons' and demonstrates patience with underperforming holdings based on long-term conviction.